Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab

Next Previous
Search
Trial Profile

Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Tocilizumab (Primary) ; Methylprednisolone
  • Indications Giant cell arteritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GUSTO

    • Most Recent Events

    • 15 Nov 2023 Results assessing vascular and musculoskeletal inflammation using MRI, presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results assessing evolution of intima-media thickness after discontinuation of Tocilizumab reporting data up to week 156 (two-year drug-free follow-up) presented at the 24th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Results assessing the efficacy and safety of TCZ monotherapy after a 3-day GC pulse in new onset Giant-cell-arteritis presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top